Dhibar, 317 patient HCQ prophylaxis study: 41% fewer cases [p=0.03] and 44% fewer symptomatic cases [p=0.21] https://c19p.org/dhibar
copied to clipboard
Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality? The PEP-CQ Study
et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106224
41% reduction in cases with HCQ PEP. Prospective open label trial with 132 HCQ patients and 185 control patients showing RR 0.59, p=0.03. 50% reduction in PCR+ cases, 44% reduction in symptomatic cases. No serious adverse events. Relatively low dosage, the PEP group received HCQ 800mg on day one followed by 400mg once weekly for 3 weeks. NCT04408456.
|
risk of case, 41.0% lower, RR 0.59, p = 0.03, treatment 14 of 132 (10.6%), control 36 of 185 (19.5%), NNT 11, adjusted per study.
|
|
risk of case, 50.0% lower, RR 0.50, p = 0.04, treatment 10 of 132 (7.6%), control 28 of 185 (15.1%), NNT 13, adjusted per study, PCR+.
|
|
risk of symptomatic case, 43.9% lower, RR 0.56, p = 0.21, treatment 6 of 132 (4.5%), control 15 of 185 (8.1%), NNT 28, adjusted per study.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Dhibar et al., 11/6/2020, prospective, India, South Asia, peer-reviewed, 13 authors, trial NCT04408456.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.